Breast cancer therapy for BRCA1 carriers: Moving towards platinum standard?

Hereditary Cancer in Clinical Practice

Volumn 7, Issue 1, 2009, Pages

  Imyanitov, Evgeny N ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CISPLATIN;

BREAST CANCER; CANCER STAGING; CLINICAL TRIAL (TOPIC); DRUG CHOICE; DRUG SENSITIVITY; HETEROZYGOTE; NOTE; PATIENT SELECTION;

EID: 77953411718     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-7-8     Document Type: Note

References (14)

1. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, Kladny J, Gorski B, Lubinski J, Narod SA. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2008, 18649131 .
2. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002, 39:608-610. 1735193, 12161606, 10.1136/jmg.39.8.608.
3. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96:1659-1668.
4. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006, 5:135-142. 10.1007/s10689-005-2832-5, 16736282.
5. Di Leo A, Claudino WM, Pestrin M, Licitra S, Biganzoli L. Using specific cytotoxics with a targeted mind. Breast 2007, 16(Suppl 2):S120-126. 10.1016/j.breast.2007.07.021, 17720501.
6. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584. 10.1038/nrc2167, 17625587.
7. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin?. Cell Cycle 2008, 7:1353-1359.
8. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8:193-204. 10.1038/nrc2342, 18256616.
9. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008, 18:80-86. 10.1016/j.gde.2008.01.016, 18343102.
10. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008, 14:7917-7923. 2652879, 19047122, 10.1158/1078-0432.CCR-08-1223.
11. Imyanitov EN, Moiseyenko VM. Molecular-based choice of cancer therapy: realities and expectations. Clin Chim Acta 2007, 379:1-13. 10.1016/j.cca.2007.01.006, 17306783.
12. Wysocki PJ, Korski K, Lamperska K, Zaluski J, Mackiewicz A. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit 2008, 14:SC7-10.
13. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Narod SA, Lubinski J, . Polish Hereditary Breast Cancer Consortium Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008, 108:289-296. 10.1007/s10549-007-9600-1, 17492376, Polish Hereditary Breast Cancer Consortium.
14. Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007, 18(Suppl 6):vi93-8. 10.1093/annonc/mdm234, 17591843.